RxDoctor Payments Data

Scott Hardoon, MD

Internal Medicine · Melbourne, FLNPI 1427209147

Payments from drug & device makers

$1,211in general payments, 2019–2025

Across 58 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$327
  • Phathom Pharmaceuticals, Inc.$178
  • AbbVie$154
  • Astellas Pharma US Inc$140
  • Lilly USA, LLC$79
  • Johnson & Johnson$62
  • plus $270 from 12 others

What the payments were for

  • Food & beverage$1,11192%
  • Education$1008%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,211 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$652,164
Medicare patients
811
Services billed
13,619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide78$101,631
JanuviaSitagliptin Phosphate70$86,732
EliquisApixaban79$83,628
XareltoRivaroxaban48$55,902
JardianceEmpagliflozin36$48,168
MounjaroTirzepatide32$43,395
Repatha SureclickEvolocumab25$25,041
Tresiba Flextouch U-200Insulin Degludec14$16,032
TradjentaLinagliptin12$15,211
WegovySemaglutide12$15,100
FarxigaDapagliflozin Propanediol15$11,323
Fluticasone-SalmeterolFluticasone Propion/Salmeterol35$9,811
Atorvastatin Calcium766$9,648
VascepaIcosapent Ethyl18$8,527
Ezetimibe186$8,103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$327$116,73190 claims
MerckJanuvia$11$86,73270 claims
PfizerEliquis$13$83,62879 claims
Boehringer IngelheimJardiance, Tradjenta$17$63,37948 claims
Johnson & JohnsonXarelto$62$55,90248 claims
Lilly USA, LLCMounjaro$79$43,39532 claims
AbbVieSynthroid$154$4,39172 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →